The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors
Spectra Undergraduate Research Journal · 2022
DOI: 10.9741/2766-7227.1018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Spectra Undergraduate Research Journal, 2022. Verfasst von Shauna M. Mellor. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
This paper is a literature review of various scientific research papers, exploring the recent scientific advancement in the field of genetic engineering. The research presented is a foundational tool, building awareness on the implications of CRISPR/ Cas9 technology. CRISPR/ Cas9 was first discovered through the study of bacterial immune systems, fighting against viral infections. Manipulation of the Cas9 protein would eventually lead to target specific, gene-altering medicines for human organisms. CRISPR/ Cas 9 technology has begun to show promise as an effective treatment for certain monogenic disorders. Despite this, time is required before its efficacy as a proven genetic treatment plan. Certain drawbacks like chromosomal rearrangements and the formation of cancerous cells, reveal the potential negative consequences of CRISPR/Cas9 treatment. Careful calculations will be required to ensure the safety and specificity of this technology throughout future clinical trials.
Zitieren
APA
Mellor, S. M. (2022). The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors. Spectra Undergraduate Research Journal. https://doi.org/10.9741/2766-7227.1018
Vancouver
Mellor SM. The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors. Spectra Undergraduate Research Journal. 2022. doi:10.9741/2766-7227.1018
BibTeX
@article{Mellor2022,
author = {Mellor, Shauna M.},
title = {The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors},
journal = {Spectra Undergraduate Research Journal},
year = {2022},
doi = {10.9741/2766-7227.1018}
}
EUVIMED